Teduglutide seems effective, safe for short bowel syndrome

Teduglutide seems effective, safe for short bowel syndrome
For patients with short bowel syndrome with intestinal failure, the glucagon-like peptide 2 analogue teduglutide appears to be safe and reduces the number of days off parenteral support, according to a phase 3 study published in the December issue of Gastroenterology.

(HealthDay)—For patients with short bowel syndrome with intestinal failure (SBS-IF), the glucagon-like peptide 2 analogue teduglutide appears to be safe and reduces the number of days off parenteral support, according to a phase 3 study published in the December issue of Gastroenterology.

Palle B. Jeppesen, M.D., from Rigshospitalet in Copenhagen, Denmark, and colleagues conducted a 24-week study involving patients with SBS-IF who were given once-daily subcutaneous teduglutide (0.05 mg/kg/day; 43 patients) or placebo (43 patients). If 48-hour urine volumes exceeded baseline values by 10 percent or more, parenteral support was reduced.

The researchers found that at weeks 20 and 24 there were significantly more patients with >20 percent reduction in parenteral support volume from baseline among those in the teduglutide group (63 percent) compared with the (30 percent). The mean reduction in parenteral support volume at 24 weeks was 4.4 ± 3.8 L/week and 2.3 ± 2.7 L/week in the teduglutide and placebo groups, respectively. There was a significantly greater percentage of patients in the teduglutide group with a one-day or more reduction in the weekly need for parenteral support (54 percent) compared to the placebo group (23 percent). Plasma concentrations of citrulline, a of mucosal mass, increased with teduglutide. Treatment-emergent were similar between the two groups (two in the teduglutide group and three in the placebo group).

"Twenty-four weeks of teduglutide treatment was generally well tolerated in patients with SBS-IF," the authors write. "Treatment with teduglutide reduced volumes and numbers of days of parenteral support for patients with SBS-IF."

Several authors disclosed financial ties to NPS Pharmaceuticals and Nycomed, both of which funded the study.

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

Dapagliflozin aids glycemic control in type 2 diabetes

Mar 20, 2012

(HealthDay) -- For patients with inadequately controlled type 2 diabetes, treatment with dapagliflozin is associated with improved glycemic control, stabilized insulin dosing, and weight reductions, according ...

IV acetaminophen eases post-spinal op pain for children

Sep 23, 2012

(HealthDay)—Children and adolescents given intravenously (IV)-administered acetaminophen after major spine surgery have significantly less postoperative pain, compared with those given placebo, but administration ...

Recommended for you

Two expats die of MERS in Saudi commercial hub

3 hours ago

Two foreigners died of MERS in the Saudi city of Jeddah, the health ministry said Saturday, as fears rise over the spreading respiratory virus in the kingdom's commercial hub.

UAE reports 12 new cases of MERS

3 hours ago

Health authorities in the United Arab Emirates have announced 12 new cases of infection by the MERS coronavirus, but insisted the patients would be cured within two weeks.

Filipino tests negative for Middle East virus

15 hours ago

A Filipino nurse who tested positive for the Middle East virus has been found free of infection in a subsequent examination after he returned home, Philippine health officials said Saturday.

User comments